Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 5/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 2/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 2/20 | 0.30 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3672073 | 0.92 | SSTR5 (0.32) | SSTR5GRM2FPR2ALDH1A1GAA | |
| SCHEMBL916902 | 0.90 | SSTR5 (0.40) | SSTR5GRIN1GRIN2BFPR2PDE4D | |
| SCHEMBL3546345 | 0.89 | FPR2 (0.39) | SSTR5FPR2PDE4DALDH1A1GAA | |
| SCHEMBL3547325 | 0.89 | GRM2 (0.32) | SSTR5GRM2GRIN1GRIN2BPDE4D | |
| SCHEMBL917952 | 0.88 | FPR2 (0.42) | SSTR5GRM2GRIN1GRIN2BFPR2 | |
| SCHEMBL3679361 | 0.88 | SSTR5 (0.32) | SSTR5GRM2ALDH1A1GAADHODH | |
| SCHEMBL3672746 | 0.88 | SSTR5 (0.39) | SSTR5ALDH1A1GAADHODH | |
| SCHEMBL3678032 | 0.88 | SSTR5 (0.39) | SSTR5ALDH1A1GAADHODH | |
| SCHEMBL3547074 | 0.87 | FPR2 (0.38) | SSTR5GRM2GRIN1GRIN2BFPR2 | |
| SCHEMBL915634 | 0.87 | FPR2 (0.35) | SSTR5GRIN1GRIN2BFPR2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825147-B2 | Inhibitors of phosphodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-02 | — | — | US | claimed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | claimed |
| US-20090054382-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-26 | — | — | US | claimed |
| EP-1663999-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES, LTD. (IN) | 2006-06-07 | — | — | EP | claimed |
| US-20050075383-A1 | Inhibitors of phophodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2005-04-07 | — | — | US | claimed |
| WO-2005021515-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED (IN) | 2005-03-10 | — | — | WO | claimed |
| US-7825147-B2 | Inhibitors of phosphodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-02 | — | — | US | disclosed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | disclosed |
| US-20090054382-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-26 | — | — | US | disclosed |
| EP-1663999-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES, LTD. (IN) | 2006-06-07 | — | — | EP | disclosed |
| US-20050075383-A1 | Inhibitors of phophodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2005-04-07 | — | — | US | disclosed |
| WO-2005021515-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED (IN) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | SSTR5 1935/4885GRM2 1487/4885GRIN1 2423/4885 |
| US-20050075383-A1 | Inhibitors of phophodiesterase type-IV | PDE7A, PDE4A, PDE4B | SSTR5 3733/4885GRM2 2862/4885GRIN1 2997/4885 |
| US-20090054382-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | SSTR5 1977/4885GRM2 1442/4885GRIN1 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.